Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites
- PMID: 38227209
- DOI: 10.1007/s00592-023-02217-6
Edible traditional Chinese medicines improve type 2 diabetes by modulating gut microbiotal metabolites
Abstract
Type 2 diabetes mellitus (T2DM) is a metabolic disorder with intricate pathogenic mechanisms. Despite the availability of various oral medications for controlling the condition, reports of poor glycemic control in type 2 diabetes persist, possibly involving unknown pathogenic mechanisms. In recent years, the gut microbiota have emerged as a highly promising target for T2DM treatment, with the metabolites produced by gut microbiota serving as crucial intermediaries connecting gut microbiota and strongly related to T2DM. Increasingly, traditional Chinese medicine is being considered to target the gut microbiota for T2DM treatment, and many of them are edible. In studies conducted on animal models, edible traditional Chinese medicine have been shown to primarily alter three significant gut microbiotal metabolites: short-chain fatty acids, bile acids, and branched-chain amino acids. These metabolites play crucial roles in alleviating T2DM by improving glucose metabolism and reducing inflammation. This review primarily summarizes twelve edible traditional Chinese medicines that improve T2DM by modulating the aforementioned three gut microbiotal metabolites, along with potential underlying molecular mechanisms, and also incorporation of edible traditional Chinese medicines into the diets of T2DM patients and combined use with probiotics for treating T2DM are discussed.
Keywords: Bile acids; Branched-chain amino acids; Edible traditional Chinese medicines; Gut microbiotal metabolites; Short-chain fatty acids; T2DM.
© 2024. Springer-Verlag Italia S.r.l., part of Springer Nature.
Similar articles
-
Bile acids as a key target: traditional Chinese medicine for precision management of insulin resistance in type 2 diabetes mellitus through the gut microbiota-bile acids axis.Front Endocrinol (Lausanne). 2024 Dec 10;15:1481270. doi: 10.3389/fendo.2024.1481270. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 39720247 Free PMC article. Review.
-
Modulating the Gut Microbiota and Metabolites with Traditional Chinese Medicines: An Emerging Therapy for Type 2 Diabetes Mellitus and Its Complications.Molecules. 2024 Jun 9;29(12):2747. doi: 10.3390/molecules29122747. Molecules. 2024. PMID: 38930814 Free PMC article. Review.
-
PuRenDan alleviates type 2 diabetes mellitus symptoms by modulating the gut microbiota and its metabolites.J Ethnopharmacol. 2024 Mar 25;322:117627. doi: 10.1016/j.jep.2023.117627. Epub 2023 Dec 24. J Ethnopharmacol. 2024. PMID: 38147943
-
Scutellariae radix and coptidis rhizoma ameliorate glycolipid metabolism of type 2 diabetic rats by modulating gut microbiota and its metabolites.Appl Microbiol Biotechnol. 2020 Jan;104(1):303-317. doi: 10.1007/s00253-019-10174-w. Epub 2019 Nov 22. Appl Microbiol Biotechnol. 2020. PMID: 31758238
-
New Insights of Anti-Hyperglycemic Agents and Traditional Chinese Medicine on Gut Microbiota in Type 2 Diabetes.Drug Des Devel Ther. 2021 Nov 30;15:4849-4863. doi: 10.2147/DDDT.S334325. eCollection 2021. Drug Des Devel Ther. 2021. PMID: 34876807 Free PMC article. Review.
References
-
- Magliano DJ, Boyko EJ, committee IDFDAtes. IDF Diabetes Atlas. Idf diabetes atlas. Brussels: International Diabetes Federation© International Diabetes Federation, 2021 (2021).
-
- Aschner P, Gagliardino JJ, Ilkova H, Lavalle F, Ramachandran A, Mbanya JC et al (2020) Persistent poor glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International Diabetes Management Practices Study (IDMPS). Diabetologia 63(4):711–721 - PubMed - PMC - DOI
Publication types
MeSH terms
Grants and funding
- 20224ACB206010/Jiangxi Provincial Natural Science Foundation Key Project
- 20201BBG71006/Key Project of Jiangxi Province Science and Technology Key R&D Plan
- 2020BCG74001/Jiangxi Provincial Science and Technology Innovation Base Plan
- 20221ZDG02011/Jiangxi Provincial Science and Technology Innovation Base Plan
LinkOut - more resources
Full Text Sources
Medical